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N
ew medical device technologies have the potential to
revolutionize health care delivery in the United States.
With device technologies as diverse as the artificial lumbar
disc, fecal DNA testing, cardiac resynchronization therapy, and
coronary artery calcium measurements, the promise of new
medical devices is great, but the risks of misuse and overuse
are substantial. In spite of the ubiquity and impact of medical
technology, many physicians do not understand the process by
which these technologies appear in the marketplace and how
this differs from that for new pharmaceuticals. Indeed, the
level of evidence required for FDA approval of new devices is, in
most cases, far less stringent than for pharmaceuticals. Most
generalists do not know where to turn for evidence-based
information when a patient asks about the latest device
advertised in the local newspaper or when a specialist
recommends a high-tech solution to a common problem.
The impetus for this JGIM supplement grew out of a special
symposium on Medical Technology sponsored by the California
Technology Assessment Forum of the Blue Shield of California
Foundation that was held at the 2006 Society of General
Internal Medicine Annual Meeting. The goal of the session was
to educate general internists about how to evaluate the
effectiveness of new medical device technology and where to
turn for unbiased information. New technologies in colon
cancer screening, such as virtual colonoscopy and fecal DNA
testing, were discussed to explore broader issues surrounding
the policy and practice of medical device technology. The main
message of the symposium was the need for objective, evidence-
based assessments of new and emerging medical device tech-
nology that can inform patients, clinicians, and policymakers.
The articles published in this supplement are representative
of the spectrum of issues surrounding new technologies.
Dr. Conrad describes the tremendous potential of the biotech-
nology revolution to improve cancer screening through pro-
teomics. Dr. Feldman details the issues of FDA regulation and
technology assessment initially explored at the SGIM Sympo-
sium. A series of articles further explores these issues in the
context of implantable cardiac devices. Dr. Zhan carefully
describes the remarkable increase in the use of these devices
over the past decade, and considers some of the risks
associated with device implantation. Dr. Goldstein provides
insights into both the physician and patient perspectives on
deactivating the devices. Finally, Dr. Sulmasy argues that the
fundamental differences between implantable devices and
drugs require a new framework to adequately address the
ethical issues that arise when considering use of such devices.
Dr. Sim discusses additional differences between devices
and drugs in the context of clinical trials registration for
medical devices. Dr. Pateinaude studied the differences in
interpreting the use of new technologies by key thought
leaders; the issues identified raise important questions about
oversight and human subjects review. Finally, a series of
articles investigate the impact of medical information technol-
ogy on medical student education, physician prescribing
behavior, diagnosis, and the doctor–patient relationship.
We would like to thank the many people that worked
tirelessly to put this supplement together. Our greatest debt
is to the many authors who contributed their work and put up
with the editors endless revisions and suggestions. The selfless
contributions of the many peer reviewers were invaluable in
improving the quality of the final manuscripts. Special thanks
are owed to the JGIM Co-Editors-in-Chief, Dr. William M.
Tierney and Martha S. Gerrity, and to the Managing Editor,
Cindy Byrne for putting up with our endless questions and
patiently guiding us through the process of putting the
supplement together. We also need to thank Jennifer Lee and
Jenni Clarkson for their invaluable efforts keeping us on track
and working as a team. The supplement would not have been
possible without the support of the Blue Shield of California
Foundation and the encouragement of Lisa Payne-Simon
Deborah Schwab, and Crystal Hayling at the Foundation.
We hope that this Supplement gives readers a sense of the
many issues raised by our society’s embrace of new medical
device and information technologies and stimulates them to
learn more about this important aspect of modern medicine.
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